Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net earnings/(loss)	$ 328	$ (1,069)
Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:
Depreciation and amortization	516	513
Impairments and (gain)/loss on disposal of assets, net	883	1,764
Impairments and loss on sale of other investments	0	3
(Gain)/loss on sale of equity interest in naviHealth	0	(2)
Loss on early extinguishment of debt	0	10
Share-based compensation	69	65
Provision for bad debts	79	46
Change in operating assets and liabilities, net of effects from acquisitions and divestitures:
Increase in trade receivables	(510)	(1,193)
Increase in inventories	(1,012)	(922)
Increase in accounts payable	2,473	1,121
Other accrued liabilities and operating items, net	(845)	(206)
Net cash provided by operating activities	1,981	130
Cash flows from investing activities:
Proceeds from divestitures, net of cash sold	0	923
Acquisition of subsidiaries, net of cash acquired	10	0
Additions to property and equipment	(264)	(223)
Proceeds from disposal of property and equipment	2	11
Purchases of investments	(6)	(38)
Proceeds from investments	1	27
Proceeds from net investment hedge terminations	29	71
Net cash provided by/(used in) investing activities	(248)	771
Cash flows from financing activities:
Reduction of long-term obligations	(571)	(597)
Net tax proceeds/(withholdings) from share-based compensation	11	(26)
Dividends on common shares	(399)	(425)
Purchase of treasury shares	(1,500)	(1,000)
Net cash used in financing activities	(2,459)	(2,048)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations	(1)	(13)
Cash and equivalents reclassified from/(to) assets held for sale	0	109
Net decrease in cash and equivalents	(727)	(1,051)
Cash and equivalents at beginning of period	4,717	3,407
Cash and equivalents at end of period	$ 3,990	$ 2,356